What You Should Know:

你应该知道的：

– French deeptech startup

– 法国深度科技初创公司

Chipiron

Chipiron

today announced it has raised $17M in a Series A funding round to finalize the development of its compact, affordable MRI system.

今天宣布在A轮融资中筹集了1700万美元，以完成其紧凑且价格合理的核磁共振成像系统的开发。

– Led by

– 由

Blast

爆炸冲击波

, with participation from the

，参与方包括

EIC Fund

欧洲创新委员会基金

and

和

iXcore

iX核心

, and supported by public funding initiatives including

，并由包括以下内容在内的公共资助计划支持：

France2030

法国2030

and the

和

EIC Accelerator

EIC加速器

, the investment aims to make highly accurate MRI technology accessible worldwide.

，该投资旨在使高度精确的核磁共振成像技术在世界范围内普及。

Tackling MRI Accessibility Challenges

应对MRI可及性挑战

Magnetic Resonance Imaging (MRI) is widely regarded as the most precise medical imaging modality available, yet its use remains limited. Traditional MRI systems are large, extremely expensive, and require complex hospital infrastructure, restricting their deployment primarily to major hospitals. This lack of accessibility contributes to disparities in diagnostic capabilities and patient care.

磁共振成像 (MRI) 被广泛认为是目前最精确的医学成像方式，但其使用仍然有限。传统的 MRI 系统体积庞大、极其昂贵，并且需要复杂的医院基础设施，这使其部署主要局限于大型医院。这种可及性的缺乏导致了诊断能力和患者护理方面的差异。

The global MRI market, estimated at $10B, has the potential to double if the technology becomes more widely available..

估计规模为 100 亿美元的全球核磁共振市场，如果这项技术得到更广泛的应用，其规模有可能翻一番。

Founded in 2020 by CEO Evan Kervella and CSO Dimitri Labat, Chipiron aims to make MRI as accessible as an X-ray. The company is developing a next-generation, ultra-low-field MRI machine that is designed to be as reliable as current models but significantly more compact, mobile, and affordable – potentially 10 times less expensive than current standards.

Chipiron 由首席执行官 Evan Kervella 和首席科学官 Dimitri Labat 于 2020 年创立，目标是让核磁共振成像 (MRI) 的普及程度能够媲美 X 光。该公司正在开发一款新一代超低场 MRI 设备，其可靠性与现有型号相当，但体积更小、可移动性更强且价格更实惠——成本可能仅为现行标准的十分之一。

This breakthrough design opens up possibilities for deployment in facilities previously excluded from MRI use, such as local care centers, private clinics, and mobile units. Furthermore, the smaller size makes MRI scans feasible for patients often excluded from traditional machines, including those with pacemakers or implants, claustrophobic individuals, obese or elderly patients, and restless children..

这种突破性的设计为之前被排除在MRI使用范围之外的场所的部署开辟了可能性，例如当地的护理中心、私人诊所和移动单元。此外，更小的尺寸使得经常被传统设备排除在外的患者进行MRI扫描成为可能，包括那些装有起搏器或植入物的人、幽闭恐惧症患者、肥胖或年长者以及好动的儿童。

Expansion Plans

扩展计划

The company plans to produce its first clinical prototypes by the end of 2025 and commence investigational trials in hospital settings starting in 2026. Looking ahead three to five years, Chipiron has clear objectives: achieve an initial clinical application, secure the first FDA (US) and CE (Europe) regulatory authorizations, and deploy 100 commercial devices.

公司计划在2025年底前生产出首批临床原型，并于2026年开始在医院环境中开展研究性试验。展望未来三到五年，Chipiron目标明确：实现初步的临床应用，获得美国FDA和欧洲CE的首次监管授权，并部署100台商业设备。

The company plans a significant focus on expanding into the extensive US healthcare market, known for its adoption of innovative solutions, with the ultimate goal of establishing a new global standard in accessible medical imaging..

该公司计划大力拓展美国庞大的医疗保健市场，该市场以其对创新解决方案的采纳而闻名，最终目标是建立一个新的全球标准，实现医疗影像的普及化。